Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)
3,640.00
-45.00 (-1.22%)
At close: Apr 28, 2026
Korea Arlico Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Other Revenue | -0 | - | - | - | -0 | Upgrade
|
| Revenue | 201,204 | 190,436 | 187,155 | 167,737 | 140,157 | Upgrade
|
| Revenue Growth (YoY) | 5.65% | 1.75% | 11.58% | 19.68% | 12.30% | Upgrade
|
| Cost of Revenue | 96,974 | 90,708 | 77,038 | 60,871 | 52,672 | Upgrade
|
| Gross Profit | 104,230 | 99,728 | 110,116 | 106,866 | 87,485 | Upgrade
|
| Selling, General & Admin | 96,956 | 97,378 | 101,455 | 89,043 | 73,629 | Upgrade
|
| Research & Development | 5,467 | 4,539 | 4,180 | 6,532 | 8,194 | Upgrade
|
| Amortization of Goodwill & Intangibles | 267.05 | 91.49 | 79.97 | 82.7 | 81.82 | Upgrade
|
| Other Operating Expenses | 228.18 | 354.96 | 211.67 | 285.4 | 180.17 | Upgrade
|
| Operating Expenses | 103,241 | 104,887 | 107,044 | 97,002 | 82,691 | Upgrade
|
| Operating Income | 989.24 | -5,159 | 3,073 | 9,864 | 4,794 | Upgrade
|
| Interest Expense | -2,156 | -2,105 | -1,587 | -968.39 | -276.95 | Upgrade
|
| Interest & Investment Income | 230.21 | 338.53 | 435.17 | 518.13 | 167.72 | Upgrade
|
| Currency Exchange Gain (Loss) | -79.77 | 236.79 | 36.71 | 141.57 | 138.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -107.66 | -192 | 1,319 | -1,019 | -213.08 | Upgrade
|
| EBT Excluding Unusual Items | -1,124 | -6,881 | 3,276 | 8,536 | 4,610 | Upgrade
|
| Gain (Loss) on Sale of Investments | 90.46 | 240.36 | 190.04 | 168.93 | 30.37 | Upgrade
|
| Gain (Loss) on Sale of Assets | -58.69 | 392.92 | 9.08 | -313.88 | 964.68 | Upgrade
|
| Other Unusual Items | - | 73.26 | - | - | - | Upgrade
|
| Pretax Income | -1,092 | -6,174 | 3,476 | 8,391 | 5,605 | Upgrade
|
| Income Tax Expense | -486.6 | -816.11 | 414.67 | 356.96 | 675.18 | Upgrade
|
| Net Income | -605.35 | -5,358 | 3,061 | 8,034 | 4,930 | Upgrade
|
| Net Income to Common | -605.35 | -5,358 | 3,061 | 8,034 | 4,930 | Upgrade
|
| Net Income Growth | - | - | -61.90% | 62.98% | -41.12% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 17 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | 0.83% | -10.92% | 11.57% | 0.18% | -0.06% | Upgrade
|
| EPS (Basic) | -40.00 | -357.00 | 203.88 | 535.00 | 327.00 | Upgrade
|
| EPS (Diluted) | -40.00 | -357.00 | 104.00 | 532.00 | 327.00 | Upgrade
|
| EPS Growth | - | - | -80.45% | 62.69% | -41.08% | Upgrade
|
| Free Cash Flow | 6,883 | -12,085 | -16,237 | -14,137 | 3,699 | Upgrade
|
| Free Cash Flow Per Share | 454.81 | -805.18 | -963.66 | -936.13 | 245.38 | Upgrade
|
| Gross Margin | 51.80% | 52.37% | 58.84% | 63.71% | 62.42% | Upgrade
|
| Operating Margin | 0.49% | -2.71% | 1.64% | 5.88% | 3.42% | Upgrade
|
| Profit Margin | -0.30% | -2.81% | 1.64% | 4.79% | 3.52% | Upgrade
|
| Free Cash Flow Margin | 3.42% | -6.35% | -8.68% | -8.43% | 2.64% | Upgrade
|
| EBITDA | 5,921 | 1,456 | 7,844 | 12,977 | 7,400 | Upgrade
|
| EBITDA Margin | 2.94% | 0.77% | 4.19% | 7.74% | 5.28% | Upgrade
|
| D&A For EBITDA | 4,932 | 6,615 | 4,772 | 3,113 | 2,606 | Upgrade
|
| EBIT | 989.24 | -5,159 | 3,073 | 9,864 | 4,794 | Upgrade
|
| EBIT Margin | 0.49% | -2.71% | 1.64% | 5.88% | 3.42% | Upgrade
|
| Effective Tax Rate | - | - | 11.93% | 4.25% | 12.05% | Upgrade
|
| Advertising Expenses | 1,030 | 1,096 | 890.82 | 294.4 | 590.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.